Experimental Cancer Therapy Shows Early Promise in Trial
A new combination therapy could reduce tumor markers for patients with metastatic cancer, according to recent Phase 2 data.
Updated on Oct. 26, 2026 in Cancer
CytoDyn presented updated Phase 2 data for its experimental cancer treatment leronlimab at the ESMO Congress 2026. The study suggests the drug, when combined with standard chemotherapy, may reduce tumor-related DNA markers in patients with metastatic cancer.
Why it matters
Researchers are investigating whether targeting CCR5 protein expression can disrupt the immune-suppressive environment tumors create to survive, potentially improving responses to existing therapies.
In a Phase 2 trial of 66 patients, researchers evaluated leronlimab alongside trifluridine, tipiracil, and bevacizumab. Preliminary results showed an 86% median reduction in circulating tumor DNA at Week 2, though the trial's final impact on overall survival remains under investigation.
The players
CytoDyn
A biotechnology company based in Vancouver, Washington, focused on developing leronlimab for oncology and immunology.
The details
Leronlimab works by inhibiting the CCR5 receptor, which is often hijacked by tumors to attract cells that suppress the immune system. By blocking this recruitment, the drug may make the tumor microenvironment less hospitable to cancer growth. In this study, researchers observed CCR5 expression in all 91 archival tumor samples analyzed, suggesting a high prevalence of the target in the studied population.
Timeline
Patient enrollment for the CLOVER study occurred between June 2025 and May 2026.
The ESMO Congress 2026 took place in Madrid from October 23-27, 2026.
Study results were presented in a poster session on October 25, 2026.
Health Landscape
This research follows a broader trend in oncology aimed at reprogramming the tumor microenvironment rather than relying solely on cytotoxic agents. These findings at the ESMO Congress represent an incremental step in testing whether CCR5 inhibition can boost the efficacy of traditional treatments.
This development is in the early research stage and does not represent an approved treatment option for patients. Individuals interested in clinical trial participation should consult with their oncologist to discuss research opportunities relevant to their specific diagnosis.
The takeaway
The study suggests targeting the CCR5 protein is a viable, safe biological approach to modifying the tumor environment in metastatic disease. Patients should prioritize conversations with their oncologists about clinical trial eligibility if seeking access to experimental therapies.
Further reading
Learn more about emerging research and clinical developments in Cancer.
